168
Participants
Start Date
August 31, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
August 31, 2014
ferric citrate
Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
University of Pennsylvania Health System, Philadelphia
Washington Nephrology Associates, Bethesda
Clinical Research & Consulting Center, LLC, Fairfax
Nephrology Associates of Northern Virginia, Inc., Fairfax
Nephrology Clinical Research Center, Charlottesville
Butler Farms Dialysis, Hampton
Piedmont Dialysis Center, Winston-Salem
Duke University Dept of Medicine/Nephrology, Durham
Metrolina Nephrology Associates, PA, Charlotte
Asheville Kidney Center, Asheville
Kidney Care Associates, LLC, Augusta
Nephrology Associates, PC, Nashville
Vanderbilt University Medical Center, Nashville
Southeast Renal Research Institute Nephrology Associates, Chattanooga
Clinical Research Limited, Canton
University of Cincinnati, Cincinnati
DaVita Dialysis Unit 494/Nephrology Specialists, PC, Michigan City
Nephrology Hypertension Clinic, PC, Dearborn
Henry Ford Hospital, Detroit
Rochester Hills DaVita Dialysis, Pontiac
Medical College of Wisconsin, Milwaukee
Circle Medical Management, Chicago
Dept of Internal Medicine, Nephrology & Hypertension, New Orleans
UT Southwestern Medical Center at Dallas, Dallas
Kidney Associates, PLLC, Houston
Med Center Dialysis, Houston
Kidney Specialists of North Houston, PLLC, Houston
Western Nephrology and Metabolic Bone Disease, PC, Westminster
University of Colorado, Aurora
Veterans Administration Greater Los Angeles Health Care System, Los Angeles
Tufts Medical Center, Boston
Western New England Renal & Transplant Associates, PC, Springfield
University of Vermont/ Fletcher Allen Health Care: Renal Services, Burlington
RCMI-Clinical Research Center, Rio Piedras
Lead Sponsor
Keryx Biopharmaceuticals
INDUSTRY